Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127358 | PMC |
| http://dx.doi.org/10.1128/AAC.46.8.2723-2726.2002 | DOI Listing |
Publication Analysis
Top Keywords
hematologic effects
4
linezolid
4
effects linezolid
4
linezolid summary
4
summary clinical
4
clinical experience
4
experience linezolid
4
linezolid associated
4
associated reversible
4
reversible myelosuppression
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!